CureVac Halts Its First mRNA-Based Covid Vaccine. The Stock Is Tumbling.

barrons logo

This copy is for your personal, non-commercial use only. To order presentation-ready copies for distribution to your colleagues, clients or customers visit

  • Order Reprints

  • Print Article

im 415471?width=620&height=413

CureVac stock fell 14.5% in premarket trading.

Guillaume Souvant/AFP via Getty Images

CureVac said early Tuesday it was halting development of its first messenger RNA-based Covid-19 vaccine, and would instead focus on the RNA-based Covid-19 vaccine it is developing with GlaxoSmithKline.

Shares of CureVac (ticker: CVAC) dived 14.5% in premarket trading.

The end of the road for the first CureVac mRNA vaccine, which it calls CVnCoV,…

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *

Back to top button